Figure 9: Differences between predicted lapatinib response vary wildly based on tissue-of-origin, when predictive models are applied across all TCGA samples. These differences do not appear to be clinically meaningful. For example, lapatinib would be expected to be predicted to be effective against breast cancers, but there are many other tissues which are predicted to be more sensitive to this drug, and there is no clinical evidence to support these predictions. Thus we do not recommend using this approach without applying a correction (see Results section), nor do we recommend directly comparing predictions between different tissues.